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ABSTRACT
In this study, we evaluated the influence of nonmyeloablative and ablative conditioning regimens on the
occurrence of acute and chronic graft-versus-host disease (GVHD). One hundred thirty-seven patients
undergoing matched-related sibling transplantations received the same GVHD prophylaxis. Myeloablative
regimens included intravenous busulfan/cyclophosphamide (n  45) and fludarabine/melphalan (n  29).
Patients in the nonmyeloablative group (n  63) received fludarabine/idarubicin/cytarabine, cisplatin/fludara-
bine/idarubicin, and fludarabine/cyclophosphamide. The actuarial rate of grade II to IV acute GVHD was
significantly higher (hazard ratio, 3.6; 95% confidence interval, 1.5-8.8) in patients receiving ablative regimens
(36%) compared with the nonmyeloablative group (12%). The cumulative incidence of chronic GVHD was
higher in the ablative group (40%) compared with the nonmyeloablative group (14%). The rates were
comparable within the first 200 days and were significantly higher in the ablative group beyond day 200 (hazard
ratio, 5.2; 95% confidence interval, 1.2-23.2). Nonrelapse and GVHD-related mortality were relatively low in
both groups. The use of the described nonmyeloablative preparative regimens was associated with a reduced
incidence of grade II to IV acute GVHD and chronic GVHD compared with the busulfan/cyclophosphamide
and fludarabine/melphalan transplant regimens. It is interesting to note that nonrelapse mortality with
nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that
achieved with standard high-dose regimens in younger patients.
© 2004 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Myeloablative (MA) doses of chemotherapy and
otal body irradiation, typically used as preparative
egimens in hematopoietic stem cell transplantation
HSCT), are associated with a high rate of morbidity
nd regimen-related mortality. In this respect, graft-
ersus-host disease (GVHD) continues to be one of
he main limitations of allogeneic transplantation
1-3]. This has largely limited the use of MAHSCT to
ife-threatening clinical indications in younger indi-
iduals without serious comorbidities. Hematologic78alignancies predominantly occur in older patients
nd often in patients with comorbidities who are not
onsidered eligible for this treatment. Nonmyeloabla-
ive (NMA) preparative regimens have recently been
eveloped as a means to reduce the morbidity related
o hematopoietic transplantation [4-7]. These re-
uced-intensity regimens provide sufﬁcient immuno-
uppression to achieve engraftment of an allogeneic
one marrow or blood stem cell graft and allow the
mmune-mediated graft-versus-malignancy effect to
ccur [8].
The syndrome of acute GVHD (aGVHD) is in
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GVHD and Conditioning Regimens
Bart related to cytokines produced in response to the
oxicity of the preparative regimen [9,10]. Intensive
egimens can result in gastrointestinal (GI) mucosal
njury with increased permeability and endotoxemia
11,12], which stimulates and ampliﬁes a cytokine cas-
ade that is central in the pathophysiology of aGVHD
12,13]. One theoretical advantage of the use of less
oxic NMA preparative regimens may be a lower in-
idence of aGVHD. Because aGVHD is a risk factor
or the development of chronic GVHD (cGVHD), its
ncidence may indirectly be reduced as well.
The effect of preparative regimen intensity on the
ncidence of aGVHD and cGVHD has not yet been
ystematically addressed. In this study, we evaluated
he inﬂuence of NMA and MA conditioning on the
ccurrence of aGVHD and cGVHD and nonrelapse
ortality (NRM) in patients undergoing matched-
elated sibling transplantations and who received the
ame GVHD prophylaxis. We tested the hypothesis
hat use of a less toxic NMA preparative regimen
ould result in lower incidence of aGVHD and
GVHD.
ETHODS
We evaluated 137 consecutive patients who re-
eived HSCT as part of prospective clinical trials
etween June 1, 1996, and September 30, 2000. All
atients received allogeneic hematopoietic transplants
rom an HLA-identical sibling donor. These studies
ere reviewed and approved by the University of
exas M.D. Anderson Cancer Institutional Review
oard, and all patients provided written informed
onsent to participate. Information was obtained from
he Department of Blood and Marrow Transplanta-
ion database, where all clinical data is systematically
ollected for every patient undergoing stem cell trans-
lantation.
Preparative regimens were considered MA if they
roduced profound pancytopenia for 28 days with-
ut transplantation and if, after transplantation, he-
atopoietic recovery was completely donor derived
complete chimerism in 80% of patients). NMA
egimens were deﬁned as those in which hematopoi-
tic recovery would reliably occur within 28 days
ithout transplantation and if, after transplantation,
ixed chimerism could be documented in most pa-
ients [8].
MA preparative regimens included (1) busulfan
.8 mg/kg intravenously (IV) every 6 hours on days
7 to 4 and cyclophosphamide 60 mg/kg on days
3 and 2 (IV BuCy) and (2) ﬂudarabine 25 mg/m2
n days 6 to 2 and melphalan 90 mg/m2 on days
3 and 2 (FM), which is MA with this dose of
elphalan. Hematopoietic transplantation occurred
n day 0.
B&MTNMA regimens included ﬂudarabine 30 mg/m2/d
n days 6 to 3, idarubicin 12 mg/m2/d on days 6
o 4, and cytarabine 2 g/m2 on days 7 to 3
FlagIda); cisplatin 100 mg/m2 IV continuous infusion
n days 6 to 3, ﬂudarabine 30 mg/m2 on days 4
nd 3, cytarabine 500 to 1000 mg/m2 on days 4
nd 3 (PFA); and ﬂudarabine 30 mg/m2 on days 5
o 3 with cyclophosphamide 750 mg/m2 on days 5
o 3 (FC). Seven patients in the FC group received
ituximab 375 mg/m2 on day13 and 1000 mg/m2 on
ays 6, 1, and 8. All these regimens have been
sed for standard chemotherapy and produce only
ransient myelosuppression without hematopoietic
ransplantation.
The BuCy regimen was intended for younger pa-
ients without serious comorbidities. The FM regi-
en was intended as a potentially better tolerated MA
egimen in older or medically inﬁrm patients. Al-
hough it was initially considered a reduced-intensity
egimen, it is now clear that its overall toxicity is
omparable to that of MA regimens; it necessitates
ematopoietic stem cell infusion for hematologic re-
overy. In this study, aGVHD, cGVHD, and GVHD-
elated mortality were similar in patients receiving
M and IV BuCy. Thus, they were analyzed as a
roup. The NMA FlagIda regimen was intended for
lder patients with myeloid leukemias, and the NMA
C and PFA regimens were used for patients of all
ges with lymphoid malignancies.
The diagnoses treated included myelodysplastic
yndrome/acute myelogenous leukemia (n  61),
hronic myelogenous leukemia/myeloproliferative
isorders (n  36), chronic lymphocytic leukemia
n  8), and non-Hodgkin lymphoma (n  32). All
atients received their grafts from HLA genotypically
dentical siblings. The cell source was peripheral
lood stem cells (PBSC) in most patients (n  113;
2%).
All patients received a common regimen of post-
ransplantation immunosuppressive therapy as pro-
hylaxis against GVHD. This included tacrolimus
tarting at day 2, with dose adjustments to maintain
lood levels of 5 to 15 ng/mL, and methotrexate 5
g/m2 on days 1, 3, and 6. Bone marrow recipients
eceived an additional dose on day 11 [14]. Tacroli-
us was continued for at least 90 days in the absence
f disease progression. Patients at low risk for relapse
ontinued tacrolimus until 6 to 9 months after trans-
lantation. Those at high risk for relapse or minimal
esidual disease had immunosuppression withdrawal
t 3 to 6 months after transplantation. If grade II to IV
GVHD developed, methylprednisolone 2 mg/kg was
enerally administered. Chronic GVHD was initially
reated with corticosteroids and tacrolimus. Patients
ith steroid-resistant aGVHD or cGVHD received
lternative immunosuppressive therapy.We deﬁned low-risk disease as the ﬁrst chronic or
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1ccelerated phase of chronic myelogenous leukemia,
cute myelogenous leukemia, or lymphoid malignan-
ies in ﬁrst complete remission and lymphoid malig-
ancies in ﬁrst chemosensitive relapse or second com-
lete remission. All other patients were considered to
ave high-risk disease.
Conditions classiﬁed as serious comorbidities in-
luded 1 or more of the following: (1) cardiac: coro-
ary artery disease, congestive heart failure, serious or
ife-threatening arrhythmias, deep venous thrombosis,
ulmonary embolism, and uncontrolled severe hyper-
ension; (2) pulmonary: emphysema, asthma, history
f acute respiratory failure necessitating mechanical
entilation and sarcoidosis; (3) renal: acute or chronic
enal failure and hydronephrosis; (4) infections: fungal
Aspergillus species, Candida species, Torulopsis gla-
rata, or Fusarium species), viral (cytomegalovirus,
aricella-zoster virus, or herpes simplex virus), myco-
acterial (tuberculosis or myobacterium avium inter-
ellulare), Pneumocystis carinii, and serious bacterial
nfections (septic shock or osteomyelitis); and (5)
ther conditions: pancreatitis, history of GI bleeding,
troke, seizures, other cancers, autoimmune condi-
ions (inﬂammatory bowel disease, autoimmune he-
olytic anemia, or GVHD in a previous transplant).
VHD Assessment
GVHD was assessed in 2 ways. The ﬁrst way,
hich is the focus of this article, was to assess the
ccurrence of GVHD before immune manipulation to
etter determine the effect of the preparative regimen
n the occurrence of GVHD. In this case, aGVHD
as evaluated within 100 days after HSCT. The stag-
ng and grading of aGVHD was performed according
o modiﬁed Glucksberg consensus criteria [15]. Bi-
psy samples from involved tissues were obtained in
ll 29 patients with grade II to IV aGVHD. The
iagnosis of aGVHD was conﬁrmed histologically in
4 (83%) of 29 patients with grade II to IV aGVHD.
eventeen (55%) of 31 skin biopsy samples were pos-
tive and conﬁrmed the diagnosis of skin GVHD in 17
f 18 patients. The remaining patient had a negative
kin biopsy with a simultaneous positive GI biopsy.
ourteen (70%) of twenty upper and lower GI biop-
ies conﬁrmed the diagnosis of GI GVHD in 8 of 12
atients with clinical manifestations of GI GVHD. Six
50%) liver biopsies conﬁrmed the diagnosis of liver
VHD in all 5 patients with abnormal bilirubin and
lkaline phosphatase. The remaining patient had con-
omitant positive skin and GI biopsies. The diagnosis
f cGVHD was based on clinical manifestations, in-
luding sicca syndrome, lichenoid changes on mucosal
urfaces, lichenoid skin GVHD, sclerodermal GVHD,
nd GI strictures. Diarrhea or liver function abnor-
alities were considered part of the spectrum of
GVHD if they occurred beyond 100 days after the m
80ast stem cell infusion and in the presence of a positive
iopsy of the GI tract or liver, respectively. Chronic
VHD was classiﬁed as de novo, progressive, or re-
apsing [3]. De novo cGVHD was deﬁned as occur-
ing without a history of aGVHD. For relapsing
GVHD, cGVHD developed after a history of
GVHD that was successfully treated into complete
emission. Patients with progressive cGVHD had
GVHD that failed to achieve remission with treat-
ent and progressed into cGVHD.
Second, we determined the incidence of all
VHD (ie, acute or chronic) without censoring at the
ime of immune manipulation. Only mortality was
onsidered as a competing risk. Thus, we included
VHD that occurred after immune manipulation in
oth the MA and NMA groups.
himerism
Hematopoietic chimerism was evaluated on bone
arrow cells by restriction fragment length polymor-
hisms at the AY-29 or YNH24 loci and by cytoge-
etic studies in sex-mismatched cases [16]. These as-
ays are able to detect mixed chimerism if more than
% recipient or donor cells are present. Lineage-
elated chimerism studies were not available on all
atients and were not considered in this analysis.
ortality
GVHD-related mortality included death second-
ry to aGVHD or cGVHD independently of whether
VHD occurred before or after immune manipula-
ion. Deaths due to infection in the setting of GVHD
r in patients who were receiving immunosuppressive
reatment for GVHD were also included in this
roup. NRM included all deaths unrelated to the
ecurrence or progression of malignancy.
tatistical Analysis
The primary objective of the analysis was to assess
he incidence of GVHD according to the intensity of
he conditioning regimen while the patient received
tandard GVHD prophylaxis. For this purpose, the
rimary end points of the study were the incidence of
rade II to IV aGVHD and cGVHD before immune
odulation (including withdrawal of immune sup-
ression) or donor lymphocyte infusions (DLI). Sec-
ndary end points were GVHD-related mortality,
RM, and the overall incidence of GVHD irrespec-
ive of immune modulation. The incidences of
VHD, GVHD-related mortality, and NRM were
stimated by the method of Prentice et al. [17] to
ccount for the differences in immune modulation,
elapse, or mortality rates in the different condition-
ng regimens. Competing risks for the occurrence of
VHD before manipulation were withdrawal of im-
unosuppression, DLI, disease progression, and
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GVHD and Conditioning Regimens
Beath without GVHD. In addition, the occurrence of
GVHD was considered a competing risk for the
stimation of the cumulative incidence of de novo
GVHD. Follow-up time was censored at the earliest
f these events. Only death without GVHD was a
ompeting risk for the estimation of the overall inci-
ence of GVHD irrespective of immune manipula-
ion, and only progression of malignancy was consid-
red a competing risk for NRM.
Median follow-up among survivors was 20 months
range, 6-48 months) overall, 19 months (range, 8-48
onths) for the ablative group, and 23 months (range,
-42 months) for the reduced-intensity group (P 
4). To ensure comparable follow-up time for the 2
onditioning regimen groups, we report the incidence
f cGVHD at 18 months. NRM was estimated at 2
ears.
The Cox proportional hazards model was used to
ompare the outcomes of interest among patients re-
eiving MA and NMA regimens. It was not possible to
djust for confounding by using multivariate analysis
ecause of the sample size. Adjustment was therefore
imited to bivariate analysis, when possible, with pre-
arative regimen as a constant covariate. In addition,
he distribution of potential confounding factors (age,
tem cell source, diagnosis, and chimerism at day 30)
as skewed in the NMA group (described below).
his further limited our ability to conduct multivari-
te analysis. Adjustment for confounding in this case
as limited to restricting the comparison of the regi-
en groups to the categories of the covariates that
able 1. Patient Characteristics
Variable
Overall
(n  137)
ex (M/F) 85/52
ge (y)
Median 53
Range 15-75
o. patients >40 y (%) 105 (77)
iagnosis, n (%)
AML/MDS 61 (45)
CML 36 (26)
CLL 8 (6)
NHL 32 (23)
ell source, n (%)
PBSC 113 (82)
BM 24 (18)
isease risk group, n (%)
High risk 65 (48)
Low risk 72 (52)
rior chemotherapy regimens
<2 88 (64)
>2 49 (36)
erious comorbidities, n (%) 63 (46)
ML indicates acute myelogenous leukemia; MDS, myelodysplast
phocytic leukemia; NHL, non-Hodgkin lymphoma; BM, boneepresented most patients in the NMA group. The .
B&MTssumption of constant proportional hazards over
ime was tested graphically [18]. When indicated, the
aximized partial likelihood method was used to ﬁnd
he appropriate time breakpoint within which the haz-
rds were proportional. Patient characteristics were
ompared by the Fisher exact and 2 tests. Two-sided
values of .05 were considered signiﬁcant. Analysis
as performed with Stata version 7.0 (Stata Corp.,
ollege Station, TX).
ESULTS
atient Characteristics
Patient characteristics varied signiﬁcantly accord-
ng to the preparative regimen (Table 1). The MA
roup patients were generally younger (median age,
5 years; P  .001). Less than half of these patients
ad high-risk disease, compared with 56% in the
MA groups (P  not signiﬁcant). Similarly, a lower
roportion of patients had serious comorbidities in
he MA (39%) compared with the NMA (54%) group
t the time of transplantation (P  not signiﬁcant).
A signiﬁcantly higher proportion of patients in the
MA group had received more than 2 chemothera-
eutic regimens before transplantation (P  .02). The
tem cell source was bone marrow in 28% of the MA
roup, compared with 5% of those receiving NMA
egimens (P  .001). In the MA group, 97% were
yeloid malignancies. However, most patients in the
MA group (61%) had lymphoid malignancies (P 
blative
n  74)
Nonmyeloablative
(n  63) P Value
47/27 38/25 NS
45 59
15-68 21-75 <.001
47 (63) 58 (92) <.001
42 (57) 19 (30)
30 (40) 6 (9)
0 8 (13)
2 (3) 30 (48) <.001
53 (72) 60 (95)
21 (28) 3 (5) <.001
30 (40) 35 (56)
44 (60) 28 (44) NS
54 (73) 34 (54)
20 (27) 29 (46) .02
29 (39) 34 (54) NS
rome; CML, chronic myelogenous leukemia; CLL, chronic lym-
; NS, not signiﬁcant.A
(
ic synd
marrow001).
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1Seven patients had graft failure and were not con-
idered at risk for GVHD; they were included only for
he estimation of NRM. Of the remaining 130 pa-
ients, those who had evidence of engraftment by
valuation of mixed or complete chimerism (at day 30
or aGVHD and at day 100 for cGVHD) or by diag-
osis of GVHD were evaluable for the incidence of
VHD. These included 123 patients for aGVHD and
25 patients for cGVHD. Four patients had aGVHD
nd 5 had cGVHD without assessment of chimerism
n day 30 and 100, respectively.
cute GVHD
Overall Incidence and Severity. The incidence of
rade II to IV aGVHD was 36% (95% conﬁdence
nterval [CI], 26%-49%) in the MA group compared
ith 12% (95% CI, 6%-25%) in the NMA group
hazard ratio [HR], 3.6; 95% CI, 1.5-8.8; Table 2;
igure 1). This effect was consistent when comparison
as performed among patients who were older than
0 years and those who received PBSCs (Table 3),
fter adjusting for the number of prior chemotherapy
egimens received or the disease risk category.
Ten patients (8%) developed grade III to IV
GVHD. The number of patients with grade III to IV
GVHD was low with all preparative regimens. The
igure 1. Cumulative incidence of acute GVHD. Patients receiving
onmyeloablative regiments were compared with those receiving
yeloablative regimens. Progression of malignancy, immunosup-
ression withdrawal, donor lymphocyte infusion, and death without
able 2. Incidence of GVHD before Immune Manipulation
Regimen n*
No. aGVHD
II-IV
In
yeloablative 67 23 34
onmyeloablative 56 6 11
otal 123 29
Patients with evidence of donor chimerism or aGVHD.
Cumulative incidence considering immune manipulation, second
Patients with evidence of donor chimerism or cGVHD.VHD were considered competing risks. *
82ncidence was higher in the MA (12%; 95% CI, 6%-
3%) than in the NMA group (4%; 95% CI, 1%-
4%), but this was not statistically signiﬁcant (P  .1).
he PFA and the FlagIda regimens had no cases of
rade III to IV aGVHD.
Organ Involvement. Skin was the organ most fre-
uently involved (n  18; 15%), followed by GI
VHD (n  12; 10%) and liver (n  5; 4%; Table 4).
hen individual regimens were analyzed for organ
nvolvement, there was a signiﬁcantly lower propor-
ion of skin involvement in the NMA group (P  .03)
nd a higher proportion of GI involvement in the FM
roup (P  .01) compared with the other regimens.
nly 5 patients with grade II to IV aGVHD had liver
nvolvement (4%). Liver was the only organ involved
n 3 patients, all of whom were in the BuCy group.
Chimerism and aGVHD. In the NMA group, 32
valuable patients (57%) had complete donor chimer-
sm, and 23 (41%) had mixed chimerism at day 30.
ost patients (89%) in the MA group had complete
onor chimerism at day 30. Among patients who had
omplete donor chimerism at day 30, the incidence of
rade II to IV aGVHD was 36% in the MA group and
9% in the NMA group (HR, 2.3; 95% CI, 0.9-6.2).
his effect is only marginally signiﬁcant, but it is
onsistent with the overall higher incidence in the MA
roup compared with the NMA group.
Among patients receiving NMA regimens, there
as a trend for a reduced rate of grade II to IV
GVHD in patients with mixed chimerism. This oc-
e†
I) n‡
No. cGVHD
at 18 mo
Incidence†
(95% CI)
48) 70 25 40% (28-58)
3) 55 7 14% (7-27)
125 32
, relapse, or death without GVHD as competing risks.
able 3. Incidence of aGVHD by Stem Cell Source, Age, and
iagnosis
Variable n*
No.
aGVHD
II-IV HR 95% CI
eripheral blood stem cells
Myeloablative 48 19 3.9 1.5-9.7
Nonmyeloablative 53 6
ge >40 y
Myeloablative 43 14
Nonmyeloablative 51 6 3 1.1-7.7
yeloid malignancy
Myeloablative 65 22
Nonmyeloablative 23 2 4.3 1.0-18.5cidenc
(95% C
% (24-
% (5-2
infusionPatients with evidence of donor chimerism or aGVHD.
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GVHD and Conditioning Regimens
Burred in 1 patient with mixed chimerism (4%) and 5
atients with complete donor chimerism (16%), but it
as not statistically signiﬁcant (HR, 0.5; 95% CI,
.1-2.4). The effect of mixed chimerism could not be
ssessed among the MA group because of the small
umber of patients.
hronic GVHD
The cumulative incidence of cGVHD at 18
onths was 40% (95% CI, 28%-58%) for the MA
roup and 14% (95% CI, 7%-27%) for patients re-
eiving NMA regimens. The increased rate among the
A group was not constant over time, and the Cox
odel assumption of constant proportional hazards
as not met. Up to day 200 after transplantation, the
ates of cGVHD were comparable in the MA and
MA groups (HR, 1.1; 95% CI, 0.4-3.4). Beyond day
00, the rate was signiﬁcantly higher for the MA
roup (HR, 5.2; 95% CI, 1.2-23.2; Figure 2). This
ffect was consistent when comparison was done
mong patients who were older than 40 years and for
hose who received PBSC, after adjusting for the
umber of prior chemotherapy regimens received or
or the disease risk category.
The cumulative incidence of de novo cGVHD was
igure 2. Cumulative incidence of chronic GVHD. Patients receiv-
ng nonmyeloablative regimens were compared with those receiving
usulfan/cyclophosphamide and ﬂudarabine/melphalan. Progres-
ion of malignancy, immunosuppression withdrawal, donor lym-
hocyte infusion, and death without GVHD were considered com-
able 4. Acute GVHD Grade II to IV: Organ Involvement
Regimen n Skin, n (%) GI, n (%) Liver, n (%)
uCy 41 8 (19) 3 (7) 3 (7)
M 26 6 (23) 6 (23)* 1 (4)
onmyeloablative 56 4 (7)* 3 (5) 1 (2)
otal 123 18 (15) 12 (10) 5 (4)
Indicates a statistically signiﬁcant difference in organ involvement
in comparison with the other preparative regimens.(eting risks.
B&MT0% (95% CI, 5%-22%) and 6% (95% CI, 2%-19%)
n the MA and NMA groups, respectively. The rates
ere not signiﬁcantly different between these 2
roups, and the HR did not vary over time (HR, 2.4;
5% CI, 0.6-9.9). This suggests that the higher rate
mong the MA group could be attributed mostly to a
igher rate of progressive and relapsing cGVHD,
ighlighting the importance of aGVHD as a risk fac-
or.
Chimerism and cGVHD. Among patients with
omplete donor chimerism at day 30, we still observed
trend for an increased rate of GVHD for the MA
roup (HR, 1.7; 95% CI, 0.7-4.2). Similarly to what
as observed in the overall group, the HR varied over
ime; however, this was not statistically signiﬁcant and
id not warrant a separate analysis before and after day
00 after transplantation.
In the NMA group, there was a trend for a lower
ate of cGVHD for patients with mixed chimerism
ompared with those with complete chimerism; 1 of
3 patients with mixed chimerism developed cGVHD,
ompared with 6 of 30 of patients with complete
himerism (HR, 0.3; 95% CI, 0.03-2.4). Similarly, the
orresponding proportions for day 100 were 1 of 24
nd 6 of 16 (HR, 0.2; 95% CI, 0.02-1.5).
VHD after Early Immunosuppression
ithdrawal and DLI
Fifty-nine patients underwent early withdrawal of
mmunosuppression for recurrence or progression of
alignancy. Nineteen of these patients additionally
eceived a DLI for disease control. Five patients re-
eived a DLI without immunosuppression withdrawal.
he proportion of patients receiving immune manip-
lation was signiﬁcantly higher in the NMA group
igure 3. Cumulative incidence of all GVHD. Patients receiving
onmyeloablative (NMA) regimens were compared with those re-
eiving myeloablative (MA) regimens. Only mortality was consid-
red a competing risk. Patients undergoing immunosuppression
ithdrawal, DLI, or both were included in both the NMA (n  44)
nd MA (n  29) groups.70%) than in the MA group (39%; P  .01). We
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1valuated all GVHD (both acute and chronic) in both
roups, including patients who underwent immune
anipulation. Overall, the MA group had a signiﬁ-
antly higher incidence of GVHD (55%) compared
ith the NMA (41%; HR, 1.8; 95% CI, 1.1-3.0; P 
03; Table 5; Figure 3).
RM and GVHD-Related Mortality
NRM at 2 years was similar for the MA (19%;
5% CI, 12%-31%) and NMA (15%; 95% CI, 8%-
9%; HR, 1.4; 95%CI, 0.6-3.3; Figure 3) groups. The
auses of NRM at 2 years are listed in Table 6. The
VHD-related mortality rate was low for both
roups: 8% (95% CI, 3%-18%) in the MA group and
% (95% CI, 3%-22%) in the NMA group (HR, 1.1;
5% CI, 0.3-4.1; Table 6).
ISCUSSION
T-cell alloreactivity remains central in the patho-
hysiology of both aGVHD and cGVHD. However,
esearch over the last decade supports additional
echanisms that involve other cell types and multiple
ytokines in the pathophysiology of aGVHD. In this
odel, the conditioning regimen causes tissue damage
nd the release of proinﬂammatory cytokines, includ-
ng tumor necrosis factor-, interleukin (IL)-1, and
L-6 [13]. Donor T cells respond to host alloantigens
ith activation and release of the T-helper 1 cytokines
L-2 and interferon-. Interferon-, in conjunction
ith endotoxins from GI bacteria that circulate sys-
emically after mucosal damage, activates macro-
hages and natural killer cells [9,12,13]. This activa-
ion results in further release of inﬂammatory
ytokines and ampliﬁes the tissue damage caused by
he immune-mediated graft-versus-host reaction [13].
In this study, we tested the hypothesis that a less
ntensive and toxic NMA regimen would be associated
ith less aGVHD and, consequently, cGVHD in pa-
ients receiving the same GVHD prophylaxis.
Comparison of GVHD that occurs after NMA
nd MA regimens is difﬁcult because of differences in
atient characteristics and risk factors for GVHD.
able 5. Cumulative Incidence of GVHD
Regimen n* No. GVH
Incidence
at 18 mo† 95% CI
yeloablative 72 38 55% 48-63
onmyeloablative 58 23 41% 29-57
otal 130 61
Excluded were patients with primary graft failure: 2 in the myelo-
ablative group and 5 in the nonmyeloablative group.
Cumulative incidence of GVHD considering mortality as a com-
peting risk.MA transplantations were developed to extend the *
84se of HSCT to older patients and those with comor-
idities who were not eligible for MA regimens. Thus,
he NMA transplant recipients were at higher risk for
GVHD and cGVHD. Many centers have used
nique posttransplantation immunosuppressive ther-
py with NMA transplants, and this precludes direct
omparison with MA regimens. Others have inten-
ionally discontinued immunosuppressive therapy
arly after NMA transplantations to enhance graft-
ersus-leukemia effects. Early termination of immu-
osuppression may be associated with a higher inci-
ence of GVHD, lower overall survival, and an
ncrease in transplant-related mortality [19].
We have chosen to use the same posttransplanta-
ion immunosuppressive therapy for NMA regimens
s with MA transplantations and to continue this ther-
py for at least 3 months in the absence of disease
rogression. This facilitates comparison of the effect
f the preparative regimen on the incidence and se-
erity of GVHD. An additional limitation to the com-
arison of regimens is the heterogeneity of the patient
nd transplant characteristics, which is inherent to the
urrent indications for NMA regimens and favors the
A group. Most patients who received NMA regi-
ens in our population were older than 40 years and
ad received PBSCs; they were therefore at an in-
reased risk of GVHD. To adjust for this heteroge-
eity, we compared outcomes within these categories
f patients because the skewed distribution precluded
he use of multivariate analysis. Differences in the
umber of prior chemotherapy regimens and the dis-
ase risk group may be additional confounders in the
omparison of the effects of preparative regimens. We
ould conduct only bivariate analysis to adjust for
hese factors because of the small sample size.
The incidence of grade II to IV aGVHD was
igniﬁcantly lower in NMA regimens compared with
he MA group. This effect was consistent among pa-
ients 40 years old, those who received PBSCs, and
hose with complete donor chimerism. It was also
ndependent of the number of prior chemotherapy
egimens or the disease risk category.
As previously reported [20], we also found that
here was a trend to a lower incidence of aGVHD in
able 6. Causes of Nonrelapse Mortality
Variable
Myeloablative
(n  74)
Nonmyeloablative
(n  63)
VHD 6* 5*
raft rejection 0 1
nfection 1 2
ultiorgan failure 3 0
emorrhage 1 0
ther 4 1
otal 15 9One death occurred beyond 18 mo after transplantation.
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GVHD and Conditioning Regimens
Batients with mixed chimerism in the NMA group.
he incidence of severe (grade III to IV) aGVHD was
ow in all regimens, and no statistically signiﬁcant
ifferences were found between groups. These con-
lusions were maintained when patients undergoing
arly withdrawal of immunosuppression, DLI, or both
ere included in the analysis.
Similarly to aGVHD, we observed a lower inci-
ence of cGVHD among patients receiving NMA
egimens. This became signiﬁcant beyond 200 days
fter transplantation. Most (76%) of the cases in the
A group were progressive or relapsing cGVHD, and
his highlights the importance of aGVHD as a risk
actor. This increased rate was independent of the
umber of prior chemotherapy regimens or the dis-
ase risk category, and it persisted among older pa-
ients and those receiving PBSC.
Differences in the incidence of GVHD were still
resent when patients who had undergone immuno-
uppression withdrawal or DLI were included in the
omparison of both groups. NRM and GVHD-re-
ated mortality were relatively low with all regimens.
t is interesting to note that NRM with NMA regi-
ens in older and more debilitated patients was low
nd comparable to that achieved with standard high-
ose regimens in younger patients.
In conclusion, the use of the described NMA pre-
arative regimens was associated with a reduced inci-
ence of grade II to IV aGVHD and cGVHD com-
ared with MA transplantation regimens. Our data
uggest that the reduction in the incidence of aGVHD
nd cGVHD is independent of factors such as older
ge, use of PBSCs, and more prior chemotherapy
reatments or advanced disease.
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